Regular Research ArticlesProgression of Cognitive, Functional, and Neuropsychiatric Symptom Domains in a Population Cohort With Alzheimer Dementia: The Cache County Dementia Progression Study
Section snippets
METHODS
The DPS was derived from the longitudinal, population-based Cache County Study on Memory in Aging (CCSMA), which has examined the prevalence, incidence, and risk factors for dementia in a U.S. county recognized for its residents' longevity.13 In its first wave, CCSMA enrolled 90% of the 5,677 county residents who were 65 years or older. Three subsequent triennial waves of case detection have been completed. As described later, most individuals with incident dementia have been followed
RESULTS
The CCSMA identified 328 individuals with incident AD. The majority of the participants were female (66%) and White (99%). Table 1 displays sample characteristics at the diagnosis visit. Participants were observed at times between 0.07 and 12.9 years after onset. Sixty-three percent died while being followed, and 4% either refused further participation or moved out of the area. The remaining 33% were active participants at the time of analysis. The mean (SD) duration of dementia from onset to
DISCUSSION
This study of a population-based, incident cohort of persons with AD found the following observations: first, that 30% to 58% of those who survived 5 to 7 years after dementia onset declined slowly; second, that AD progressed faster in women than in men; third, that number and severity of NPS increased over time but the course was variable and episodic; and fourth, that rate of change in NPS was correlated weakly, if at all, with rate of change in cognition or function.
Several studies have
References (44)
- et al.
Forecasting the global burden of Alzheimer's disease
Alzheimers Dement
(2007) - et al.
Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment
Neurol Clin
(2000) - et al.
Impact of referral bias on clinical and epidemiological studies of Alzheimer's disease
J Clin Epidemiol
(1996) - et al.
“Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician
J Psychiatr Res
(1975) - et al.
Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study
Alzheimers Demen
(2008) - et al.
Modeling dementia trajectories: an application of dynamical correlations to age-related traits in the Cache County Dementia Progression Study
Alzheimers Demen
(2008) - et al.
Effects of cardiovascular medications on rate of functional decline in Alzheimer disease
Am J Geriatr Psychiatry
(2008) - et al.
Progress in clinical neurosciences: cognitive markers of progression in Alzheimer's disease
Can J Neurol Sci
(2005) - et al.
Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project
Int J Geriatr Psychiatry
(1998) - et al.
Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples
J Am Geriatr Soc
(1996)
A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia
Arch Neurol
The consortium to establish a registry for Alzheimer's disease (CERAD), Part IV: rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease
Neurology
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration
Am J Psychiatry
Prognosis of Alzheimer's disease: the Rotterdam Study
Neuroepidemiology
Person-specific paths of cognitive decline in Alzheimer's disease and their relation to age
Psychol Aging
APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease
Neurology
APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study
Neurology
The Modified Mini-Mental State (3MS) examination
J Clin Psychiatry
An adaptation of the modified Mini-Mental State Examination: analysis of demographic influences and normative data: the Cache County study
Neuropsychiatry Neuropsychol Behav Neurol
A validation study of the Dementia Questionnaire
Arch Neurol
Dementia diagnoses from clinical and neuropsychological data compared: the Cache County study
Neurology
Diagnostic and Statistical Manual of Mental Disorders
Cited by (187)
The Neuropathological Underpinnings of Neuropsychiatric Symptoms in Dementia
2024, American Journal of Geriatric PsychiatryGlobal cognitive trajectory patterns in Alzheimer's disease
2024, International PsychogeriatricsMalnutrition and neuropsychiatric symptoms in dementia: The Cache County Dementia Progression Study
2023, International PsychogeriatricsAcetyl-cholinesterase-inhibitors reconsidered. A narrative review of post-marketing studies on Alzheimer’s disease
2024, Aging Clinical and Experimental ResearchMinding the Gap: Exploring Neuroinflammatory and Microglial Sex Differences in Alzheimer’s Disease
2023, International Journal of Molecular SciencesNeuropsychiatric symptoms in people living with dementia receiving home health services
2023, Journal of the American Geriatrics Society
Authors disclosure: Peter V. Rabins: Legal testimony for Janssen Pharmaceutical; Martin Steinberg: Grant support from NIA and Elan Pharmaceuticals; Kathleen A. Welsh-Bohmer: 1) Scientific advisory board for Medivation, Inc. 2) Received funding for travel and speaker honoraria from Medivation, Inc., and Elan Corporation/Wyeth. 3) Has served/serves as an associate editor of Neuropsychology Review, on the editorial boards of Alzheimer's & Dementia, the Journal International Neuropsychological Society, and the Journal of Experimental and Clinical Neuropsychology, and as a consulting editor for Aging, Neuropsychology, and Cognition and Neuropsychology. 4) Holds US Patent #6867236 (issued 2005): Nonsteroidal Anti-inflammatory drugs for the treatment of Alzheimer's disease. 5) Receives royalties from the publication of Geriatric Neuropsychology: Assessment and Intervention (Guildford Publications, 2006). 6) Receives research support from the NIH (NIA AG11380 [PI] and NIA AG028377 [PI]); Constantine Lyketsos: 1) Grant support (research or CME)—NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis. 2) Consultant/Advisor—Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Genentech. 3) Honorarium or travel support—Pfizer, Forest, Glaxo-Smith Kline, Health Monitor; JoAnn Tschanz, Chris Corcoran, Sarah Schwartz, Katherine Treiber, Robert Green, Maria Norton, Michelle Mielke, Kathleen Piercy, Jeanne-Marie Leoutsakos, and John C.S. Breitner have no disclosures.